Liquidia Announces Long-Term Clinical Timelines for PH-ILD and L606 NDA Submission
Liquidia Corporation (LQDA) has outlined its long-term clinical development roadmap, targeting the completion of enrollment for its pulmonary hypertension interstitial lung disease (PH-ILD) program by 2028. Following this milestone, the company aims to submit a New Drug Application (NDA) for L606 in 2029. During recent management commentary, CEO Roger Jeffs highlighted the strong commercial performance of YUTREPIA, noting five consecutive quarters of growth across prescriptions, revenue, and adjusted EBITDA. Additionally, the company signaled a reduction in legal risk following a recent settlement that addresses previous litigation overhang.
Tickers: $LQDA
Topics: EBITDA litigation settlement prescription growth revenue growth
Read the full article at Seeking Alpha
Part of the story Liquidia Announces Long-Term Clinical Timelines for PH-ILD and L606 NDA Submission (2 articles)